ENहिन्दी soon
Home/India/Blog/Why GLP-1s cost so much
INIndia Prices

Why are Mounjaro and Ozempic so expensive in India?

Patents, the 2026 generics, the price cuts that followed, what the medicines cost to make, and why no price ceiling or insurance policy brings the MRP down.

GLP Guidebook teamPublished 14 Oct 20268 min read17 sourcesWritten from published sources
What we checked17 sources, each one opened and linked to the sentence it supportsLast checked 14 Oct 2026 · Next review due 14 Apr 2027 · How we write

Written for India. Reading from elsewhere? Other country versionsComing soon

The short answer

Mostly because of patents and missing competition. Tirzepatide (Mounjaro) is still under patent in India, expected to 2036, so only Eli Lilly makes it. Semaglutide (Ozempic, Wegovy) got cheaper after its patent expired in March 2026 and Indian generics arrived. No government price ceiling applies, and insurance rarely pays.

Key takeaways

  • Semaglutide prices in India fell after its main patent expired on 20 March 2026, when Indian drugmakers launched versions up to 70% cheaper.1
  • Novo Nordisk then cut Ozempic and Wegovy prices, by 23.8% and 27% on average, and Ozempic 0.25 mg fell from ₹8,800 to ₹5,660 for a pen of 4 doses.3
  • Tirzepatide, the medicine in Mounjaro, is still under patent in India, with the main patent expected to expire in 2036.5
  • A 2024 study estimated that GLP-1 medicines could be made and sold at a profit for $0.75 to $72.49 a month, well below prices in 13 countries.10
  • Semaglutide and tirzepatide are not on India's 2022 essential medicines list, and standard health insurance pays only for hospital stays.11,14
On this page
  1. What do GLP-1 medicines cost in India now?
  2. Why did semaglutide get cheaper in 2026?
  3. Why does Mounjaro still cost more?
  4. What does it cost to make these medicines?
  5. Does the government control GLP-1 prices?
  6. Why doesn't insurance bring the cost down?
  7. Questions people ask
  8. How we researched this
Before you go further
  • All GLP-1 medicines are prescription-only. A government statement on 1 Apr 2026 said only endocrinologists, internal-medicine specialists and cardiologists can prescribe them.16
  • Prices here are MRPs, the printed maximum retail price, never a seller's discount. We list brands to explain prices, not to rank them.
  • A cheaper medicine is not automatically the right one: that is a medical choice. See Guide 6.

What do GLP-1 medicines cost in India now?

A pen of 4 weekly doses has a printed MRP from ₹5,660 for Ozempic or Wegovy at the starting dose, to ₹25,781 for Mounjaro at 15 mg.3,9

  • Mounjaro (tirzepatide): ₹13,125 to ₹25,781 a KwikPen.9 A year at 15 mg is ₹3,35,153 (13 pens, our arithmetic).
  • Wegovy (semaglutide): ₹5,660 to ₹16,400 a pen.3 A year at 2.4 mg is ₹2,13,200.
  • Ozempic (semaglutide): ₹5,660 to ₹9,100 a pen.3
  • Indian generic semaglutide: pens from ₹1,800 for 4 starting doses (Alkem), and vials from ₹1,290 a month (Natco).4,2

Doctor visits and blood tests come on top. What a year costs, all in adds them up for each medicine and dose.

Why did semaglutide get cheaper in 2026?

Its main Indian patent expired on 20 March 2026. Indian companies launched their own versions, and Novo Nordisk cut its prices within days.

Once semaglutide's patent ran out, at least half a dozen Indian drugmakers launched versions, some up to 70% cheaper, Reuters reported.1 Natco opened with vials from ₹1,290 a month on the day the patent expired.2

Novo Nordisk answered within days. Ozempic and Wegovy at 0.25 mg fell to ₹5,660 for a pen of 4 doses, from ₹8,800 and ₹10,848.3 The average cut was 23.8% for Ozempic and 27% for Wegovy.3 Emcure cut Poviztra, Novo's second semaglutide brand, by 55% at the starting dose.15

Reuters described the cuts as a response to competition from cheaper generics.1 What changed, brand by brand, is in what changed when the patent expired.

Why does Mounjaro still cost more?

Tirzepatide is still under patent in India, so Eli Lilly faces no generic competition. The main patent is expected to run until 2036.5

The Medicines Patent Pool, a public-health body, says the main tirzepatide patent is granted in India.5 Lilly's second brand, Yurpeak, is sold by Cipla, but Lilly makes it and Cipla said its price would match Mounjaro's.6 Our answer Is there a generic Mounjaro in India? covers what is sold online as "generic tirzepatide".

Mounjaro's MRP has fallen once, through tax. The KwikPen launched in August 2025 at ₹14,000 for 2.5 mg.7 GST on most medicines then fell from 12% to 5% from 22 September 2025.8 Today's ₹13,125 is the launch price with that tax change applied (₹14,000 × 105 ÷ 112, our arithmetic).9 We found no Lilly price cut beyond it.

Free toolWork out your own 6- and 12-month cost

Pick a medicine and dose steps; it adds MRPs, doctor visits and tests. No sign-up.

Open the calculator

What does it cost to make these medicines?

Far less than they sell for, by one estimate. A 2024 study put sustainable prices for GLP-1 medicines at $0.75 to $72.49 a month, including a profit.10

The researchers added up the cost of the active ingredient, making the finished product, running costs, tax and a profit margin, in 2023 US dollars.10 Those prices were "substantially lower" than what the medicines sold for in the 13 countries they surveyed.10 They concluded that strong generic competition could bring prices down.10

A model is not a price list. It shows the estimated gap between making a medicine, with a profit, and what it sells for.10

Does the government control GLP-1 prices?

Not with a ceiling. The government fixes ceiling prices for medicines on India's National List of Essential Medicines, and no GLP-1 medicine is on it.13,11

  • The essential list. The 2022 list's diabetes section has glimepiride, insulins, metformin and teneligliptin, and no GLP-1 medicine.11 Semaglutide is not on it, and no government health scheme covers it, BusinessToday reported.12
  • Price rises. For non-scheduled medicines, the price regulator NPPA limits MRP rises to 10% a year.13
  • Tax. GST on most medicines has been 5% since 22 September 2025, down from 12%.8

Why doesn't insurance bring the cost down?

Standard Indian health insurance pays when you are admitted to hospital, and GLP-1 medicines are taken at home every week.14

Some policies add an outpatient (OPD) benefit; what it pays for depends on the policy.14 Does health insurance cover GLP-1 medicines in India? goes through policy types, and the insurance hub collects what we know.

Questions people ask

Why is semaglutide cheaper than tirzepatide in India?

Semaglutide's main Indian patent expired on 20 March 2026, and Indian companies launched their own versions. Tirzepatide's main patent is expected to run to 2036, and only Eli Lilly makes it, sold as Mounjaro and as Yurpeak through Cipla.1,5,6

Will Mounjaro get cheaper in India?

We found no announced price cut. Its MRP fell once, in September 2025, when GST on most medicines dropped from 12% to 5%. The main tirzepatide patent is expected to last until 2036.7,8,5

Why does Wegovy cost less than when it launched?

Wegovy launched in India in June 2025 at ₹17,345 to ₹26,050 a month. By March 2026 its pens were ₹10,850 to ₹16,400. After the patent expired and generics arrived, Novo Nordisk cut the lower strengths, to ₹5,660 to ₹16,400.17,3

Does the government fix the price of Ozempic or Mounjaro?

No. Neither is on India's National List of Essential Medicines, last revised in 2022. For medicines outside price ceilings, the government caps price rises at 10% a year.11,12,13

Does health insurance pay for Mounjaro or Ozempic?

Usually not. Standard Indian health insurance pays when you are admitted to hospital, and these are outpatient medicines.14

How we researched this

On 14 October 2026 we read dated reports of the 2026 semaglutide launches and Novo Nordisk's price cuts, the makers' releases, the Medicines Patent Pool's tirzepatide page, the 2022 essential medicines list, the GST Council's 2025 decision and statements on India's price-control rules. The manufacturing-cost estimate is from a peer-reviewed 2024 study.

Prices are MRPs from our price index. We found no Lilly statement on Mounjaro prices after the 2025 tax change, and no published Indian figure for what any maker spends to produce a pen.

Before you move on

  • Semaglutide got cheaper after its Indian patent expired in March 2026.
  • Tirzepatide's main Indian patent is expected to last until 2036, and Lilly is its only maker.
  • Ceiling prices cover medicines on the essential list, and GLP-1s are not on it; their price rises are capped at 10% a year.
  • Standard health insurance pays for hospital stays, not weekly medicines at home.
Prices in Guide 6InsuranceCost calculatorAll GLP-1 prices

More from the India blog

INIndiaPricesWhat does a year on Ozempic, Mounjaro or Wegovy cost in India, all in? INIndiaNews and rulesWhat changed for Ozempic when semaglutide's patent expired in India? INIndiaPricesDoes health insurance cover GLP-1 medicines in India?
About GLP Guidebook

The monthly India update

An independent guide to GLP‑1 medicines. We don't sell medicines, take drug-company money or earn clinic commissions. Once a month: new brands, price changes, approvals and recalls. How we write

Was this post easy to understand?

Sources

  1. ThePrint (Reuters). Novo Nordisk again cuts Ozempic, Wegovy prices by up to 48% in India as generics flood market (patent expired 20 March 2026; "At least half a dozen Indian drugmakers, including Dr Reddy's, Zydus and Sun Pharma" launched versions "up to 70% cheaper in some cases"; weekly prices from a Novo Nordisk statement). 1 April 2026. Link
  2. BusinessToday. Natco opens semaglutide market at ₹1,290 (vials from ₹1,290 a month for lower strengths to ₹1,750 for the highest; "the day key patents on semaglutide expired in India"). 20 March 2026. Link
  3. Business Standard. As generics wave builds up, Novo Nordisk slashes Ozempic, Wegovy prices (0.25 mg "priced at ₹5,660 per month, down from ₹8,800 and ₹10,848"; Ozempic ₹5,660 to ₹9,100, "average decline of 23.8"; Wegovy ₹5,660 to ₹16,400, "average reduction of 27 per cent"). 31 March 2026. Link
  4. Alkem Laboratories. Press release: semaglutide injection launched in India, pre-filled pen of four doses "at an affordable price starting INR 1,800". 21 March 2026. PDF
  5. Medicines Patent Pool. Tirzepatide ("The primary patent on tirzepatide has been granted in at least 37 LMICs, including India ... with an expected expiry in 2036"). Checked 14 October 2026. Link
  6. Cipla. Cipla launches Yurpeak (tirzepatide) ("Lilly will manufacture and supply Yurpeak to Cipla, and the price will be the same as Mounjaro"). Press release, 10 December 2025. PDF
  7. Business Standard (Rimjhim Singh). Mounjaro KwikPen by Lilly debuts in India at ₹14,000 for diabetes, obesity (2.5 mg ₹14,000; 12.5 and 15 mg ₹27,500). 13 August 2025. Link
  8. Press Information Bureau, Ministry of Finance. Recommendations of the 56th meeting of the GST Council ("Reduction of GST on all other drugs and medicines from 12% to 5%"; from 22 September 2025). 3 September 2025. PDF
  9. PharmEasy, Tata 1mg, Medkart and MrMed product listings, printed MRP of the Mounjaro KwikPen (4 doses): 2.5 mg ₹13,125; 5 mg ₹16,406; 15 mg ₹25,781. Recorded in our price index, checked 11 October 2026. Not linked: we don't link pages that sell medicines.
  10. Barber MJ, Gotham D, Bygrave H, Cepuch C. Estimated sustainable cost-based prices for diabetes medicines. JAMA Netw Open 2024;7(3):e243474 (cost-based prices "from $0.75 to $72.49 per month for GLP1As", "substantially lower than current prices in the 13 countries surveyed"; 2023 US dollars). DOI · PMID 38536176
  11. Ministry of Health and Family Welfare. National List of Essential Medicines 2022, section 18.3 (medicines used in diabetes: glimepiride, insulins, metformin, teneligliptin; no GLP-1 medicine listed). PDF
  12. BusinessToday. India's weight loss drug moment: what happens when semaglutide goes generic ("Semaglutide is not on India's National List of Essential Medicines and is not covered under any government health scheme"). 20 March 2026. Link
  13. Medical Dialogues (Kamal Kant Kohli). NPPA regulated prices of 2,295 essential drugs over five years, says govt (minister's reply: NLEM "is incorporated as Schedule-I to the Drugs (Prices Control) Order, 2013"; NPPA "fixes the ceiling prices of these scheduled medicines"). 30 July 2025. Link. Also Medical Dialogues. Drugmakers cannot raise price of non-scheduled formulations by more than 10 pc yearly, minister informs Parliament ("all manufacturers of Scheduled medicines (branded or generic) have to sell their products within the ceiling price fixed by the Government"). 5 July 2019. Also Department of Pharmaceuticals, review order on Torrent (para 4.4: for non-scheduled formulations the "maximum limit fixed for increase in maximum retail price (MRP) is ten percent of MRP during preceding twelve months"). Link · PDF
  14. Niva Bupa. All about health insurance exclusion list updated from IRDAI ("Standard health insurance only pays out if you are admitted for medical treatment"). Checked 14 October 2026. Link
  15. Indian Pharma Post (IPP Bureau). Emcure Pharma reduces Poviztra starting dose price by 55% in India (0.25 mg from ₹8,790 to ₹3,999 a month). 2 April 2026. Link
  16. Press Information Bureau (PIB Research). GLP-1 Drugs: Use, Risks, and Regulation ("In India, GLP-1 drugs can only be prescribed by endocrinologists, internal medicine specialists, and cardiologists"). 1 April 2026. PDF
  17. Deccan Herald (PTI). Novo Nordisk launches anti-obesity drug Wegovy in India ("monthly price of Rs 17,345-26,050"). 24 June 2025. Link

Last checked 14 Oct 2026 · Next review due 14 Apr 2027 · Report an error

How this post was made. Written by the GLP Guidebook team from the sources above. It's general information, not medical advice. Talk to a qualified doctor before starting, stopping or changing any medicine. How we write